SCHEMBL12409290

SCHEMBL12409290

CC(=O)Nc1cccc(-c2cnc3c(NCc4ccc(S(N)(=O)=O)cc4)nccn23)c1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TTK P33981 4/20 0.46
ZAP70 P43403 1/20 0.45
CA2 P00918 1/20 0.44
FYN P06241 7/20 0.43
NTRK1 P04629 2/20 0.43
BMPR2 Q13873 2/20 0.43
TBK1 Q9UHD2 2/20 0.43
TYK2 P29597 2/20 0.43
NUAK1 O60285 1/20 0.43
STK16 O75716 1/20 0.43
CSNK2A2 P19784 1/20 0.43
AAK1 Q2M2I8 1/20 0.43
NUAK2 Q9H093 1/20 0.43
MKNK2 Q9HBH9 1/20 0.43
BMP2K Q9NSY1 1/20 0.43
RET P07949 1/20 0.43
RIPK2 O43353 1/20 0.42
CSF1R P07333 1/20 0.41
BRAF P15056 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12409245 0.90 TTK (0.49) TTKZAP70CA2FYNNTRK1
SCHEMBL12409258 0.90 TTK (0.53) TTKZAP70CA2
SCHEMBL12409293 0.88 CYP1A2 (0.47) TTKZAP70FYN
SCHEMBL12409304 0.86 TTK (0.48) TTKZAP70CA2NTRK1
SCHEMBL12409313 0.85 TTK (0.49) TTKZAP70CA2FYNNTRK1
SCHEMBL12409306 0.84 SYK (0.49) TTKZAP70NTRK1
SCHEMBL12409310 0.84 TTK (0.57) TTKZAP70CA2
SCHEMBL12409251 0.83 ZAP70 (0.50) TTKZAP70CA2
SCHEMBL12409303 0.82 TTK (0.49) TTKZAP70CA2NTRK1RET
SCHEMBL3469970 0.82 BRAF (0.57) TTKFYNBRAF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8362018-B2 Substituted imidazo[1,2-a]pyrazine compounds useful for the treatment of viral infections BIOFOCUS DPI, LTD. (GB) 2013-01-29 US disclosed
US-8362018-B2 Substituted imidazo[1,2-a]pyrazine compounds useful for the treatment of viral infections BIOFOCUS DPI, LTD. (GB) 2013-01-29 US disclosed
US-20110166147-A1 IMIDAZOPYRAZINE COMPOUNDS BIOFOCUS DPI, LTD. (GB) 2011-07-07 US disclosed
US-20110166147-A1 IMIDAZOPYRAZINE COMPOUNDS BIOFOCUS DPI, LTD. (GB) 2011-07-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110166147-A1 IMIDAZOPYRAZINE COMPOUNDS CYP3A5, HAVCR2, CYP3A43 TTK 3239/4885ZAP70 219/4885CA2 4053/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.